Contrast Medium Market is Projected to Grow at a Reliable CAGR During Forecast to 2023
Market Overview:
As procedures like magnetic
resonance imaging (MRI) and computerized tomography (CT) scans become integral
part of disease diagnosis, the Contrast Media Market has gained considerable traction.
Contrast media or contrast agent is essentially a compound that is injected
into patients to enhance the visibility of organs during MRI. Millions of MRI
scans are conducted each year in the U.S. alone. The use of MRI in diagnosis is
so popular in the U.S. that a major portion of the nation’s healthcare cost is
attributed to MRI scans.
Most commonly used contrast
medium is metal gadolinium. Research has however pointed out that the prolonged
use of metal based contrast medium in patient who have to undergo scans often
or in children and patients with kidney problems can lead to serious adverse
effects. Therefore, the contrast medium industry is veering towards the
adoption of metal free compounds. For instance, researchers at MIT and the
University of Nebraska reportedly developed an organic molecules based contrast
medium that can prove beneficial for use in high-risk groups. Increasing
incidence of scans for better disease diagnosis and innovation the field of
contrast agents are expected to add impetus to the growth of contrast medium
market.
Get a Free Sample @ https://www.marketresearchfuture.com/sample_request/1284
Key Players:
Daiichi, NanoScan Imaging, Bayer AG, Bracco Diagnostic Inc., GE
Healthcare, Guerbet Group, Jodas Expoim, Lantheus Medical Imaging Inc., Magnus
Health, Spago Nanomedical AB, and Taejoon Pharm
Segmentation:
·
Contrast media market is segmented as type,
procedures, form, application, and route of administration.
·
Based on type, contrast media market is
classified as gadolinium-based contrast media, iodinated contrast media,
barium-based contrast media and microbubble contrast media.
·
Procedure based contrast media market
classification includes X-ray/computed tomography, ultrasound, magnetic
resonance imaging and others.
·
Form based segmentation includes powder, tablet,
paste and liquid.
·
Based on application contrast media market is
subdivided as oncology, neurological disorders, gastrointestinal disorders,
cardiovascular disease, and other indications.
·
According to route of administration, contrast
media market classification includes rectal, oral, and injectable.
Regional Analysis:
Geographically the contrast media
market has been classified, into the Americas, Europe, Asia-Pacific, and the
Middle East & Africa.
Increasing expenditure on
healthcare and better healthcare infrastructure has led the contrast media
market in the Americas to register a dominant position. Medical imaging is
being increasingly used in the diagnosis of spinal injury, intestinal disease
and brain injuries leading to growth of contrast media industry in the region.
Research shows that a major portion of the healthcare expenditure in the U.S.
can be attributed to imaging technology usage. For instance, in the U.S. 118
MRIs were performed for every 1000 patients whereas in other countries the rate
was 82 MRIs for every 1000 patients. The U.S. also performed a greater number
of CTs amounting to 245 CTs per 1000 patients whereas in other countries the
mean average was only 151 CTs for 1000 patients.
Europe is expected to hold the
second-largest position in the global contrast media market. The number of MRIs
and CT scans conducted in countries like the UK, France and Germany are higher
than anywhere else in Europe and these countries are also expected to
demonstrate faster revenue growth in the contrast media market. The importance
of MRI scans is such that the density of MRI units in a country is considered
to be a reflection of the quality of its healthcare infrastructure. Germany has
around 34 MRI units for every million of its population. As the adoption of MRI
technology is encouraged, consequently, contrast media sales will also rise.
Asia Pacific contrast media
market is expected to register the highest CAGR as adoption of MRI and CT
technology garners traction. The expanding geriatric population and betterment
of health infrastructure in most Asian countries has created better growth
scope for contrast media market. For instance, South Korea has 29 MRI units per
million people.
The Middle East & Africa will
be increasing their share of the contrast media market due to the expanding
number of diagnostic centers, hospitals, and clinics.
Industry News:
The U.S. Food and Drug
Administration recently granted approval to Clariscan, MRI contrast agent based
on macrocyclic, ionic and gadolinium developed by GE Healthcare. Clariscan is
a gadolinium-based contrast agent used for in adult and pediatric
patients for intravenous use with MRI for spine, brain and associated
tissues to imaging of areas with disruption of the blood brain barrier and/or
abnormal vascularity. Incidentally, Clariscan is an approved contrast media
agent that is used in more than 55 countries across the globe. It is one
of the various imaging agents available in the U.S. developed by GE Healthcare.
Related Reports:
Transcatheter Market Research Report – Forecast to 2023
https://www.marketresearchfuture.com/infographics/transcatheter-market
Clinical Decision Support Systems (CDSS) Market Research Report –
Forecast to 2023
https://www.marketresearchfuture.com/infographics/clinical-decision-support-systems-market
CBD Oil Market Insights 2019-2024
Comments
Post a Comment